Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study.

Juergen Wolf,Takashi Seto,Ji Youn Han,Noemi Reguart,Edward B. Garon,Harry J.M. Groen,Daniel Shao-Weng Tan,Toyoaki Hida,Maja J.A. de Jonge,Sergey Orlov,Egbert F. Smit,Pierre-Jean Souquet,Johan Vansteenkiste,Monica Giovannini,Sylvie Le Mouhaër,Anna Robeva,Maeve Waldron-Lynch,Rebecca S. Heist

Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study.

2019

Juergen Wolf
Takashi Seto
Ji Youn Han
Noemi Reguart
Edward B. Garon
Harry J.M. Groen
Daniel Shao-Weng Tan
Toyoaki Hida
Maja J.A. de Jonge
Sergey Orlov
Egbert F. Smit
Pierre-Jean Souquet
Johan Vansteenkiste
Monica Giovannini
Sylvie Le Mouhaër
Anna Robeva
Maeve Waldron-Lynch
Rebecca S. Heist

9004Background: Capmatinib is a highly potent and selective MET inhibitor. Previous data of GEOMETRY mono-1 study showed a clinically meaningful overall response rate (ORR) and manageable toxicity ...

Keywords:

Capmatinib
non-small cell lung cancer (NSCLC)
Geometry
Toxicity
Medicine
overall response rate

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations